Novo Nordisk Foundation Cellerator

What Novo Nordisk Foundation Cellerator does

Novo Nordisk Foundation Cellerator is building Denmark's first dedicated facility for the development and GMP-compliant manufacturing of cell therapies at scale for Phase I/II clinical trials. Incorporated in 2023 as a limited liability company (Novo Nordisk Foundation Cellerator P/S, CVR 44 45 05 69), it is fully owned and funded by the Novo Nordisk Foundation, with any profits reinvested into the facility rather than distributed. The company is constructing a multi-purpose, multi-product facility on the Technical University of Denmark (DTU) campus in Lyngby, with groundbreaking in May 2025 and first-client operations scheduled for October 2027.

The service portfolio spans the full cell therapy value chain: Cell Line Development & Gene Editing (including ES and iPSC lines, sourcing, qualification, and banking), Assay Development & Quality Control (characterisation, purity/impurity, potency, virus/microbiology safety testing), Process Development (adherent and suspension culture, expansion, differentiation, scaling), GMP Manufacturing for Phase I/II trials, Fill/Finish & Cryopreservation, and Regulatory Support (IND/CTA filings, agency interactions). Supporting services include shared lab and office infrastructure, centralised procurement, and a community-engagement function. The PACE (Product Acceleration to Clinical Evaluation) programme operates as an early-engagement pathway for researchers with promising pre-clinical assets.

Commercially, Cellerator is a service-based CDMO with quote-based pricing, multi-year contracts, and no publicly disclosed rates. Customers are segmented across academic researchers, venture partners, biotech and pharma companies, and technology providers; target geographies span Denmark, Europe, and international markets reached through reNEW partners in the Netherlands and Australia. The PACE programme and the biannual Cell Therapy Insights Series (co-hosted with Thermo Fisher Scientific) function as the primary top-of-funnel channels. The company is pre-revenue, has ~30+ team members in build-out phase, and operates under a non-commercial mandate that subordinates financial returns to translational impact within the Novo Nordisk Foundation's regenerative medicine strategy.

Name

Novo Nordisk Foundation Cellerator

Legal name

Novo Nordisk Foundation Cellerator

Website

https://cellerator.dk

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Novo Nordisk Foundation Cellerator is building Denmark's first dedicated GMP cell therapy development and manufacturing facility for Phase I/II clinical trials. Fully funded by the Novo Nordisk Foundation, it serves academic researchers, biotech startups, and pharma developers through an integrated service portfolio, with operations scheduled to begin in 2027.

Ownership category

akta.pro rank

Product category

Cell Therapy Contract Development and Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAGABAD

Cell Therapy CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAAAKAC

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

SECONDARYHLAGABAK

Clinical Trial Material (CTM) Manufacturing & Supply CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

• Cell therapy manufacturing
• GMP clinical production
• Cell line development
• Process development services
• Regulatory affairs support

Headquarters

HQ city

Lyngby

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Cell Therapy Manufacturing Services: Cellerator provides manufacturing and development services to cell therapy developers. The facility is established as a limited liability company fully owned and funded by the Novo Nordisk Foundation, with any profits reinvested in the facility. Services include process development, GMP manufacturing, product release, and regulatory support.
2. PACE Program Services: Early engagement program (PACE - Product Acceleration to Clinical Evaluation) offering collaboration, guidance, resources and services to researchers developing promising cell therapies to shorten the path from discovery to treatment.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Novo Nordisk Foundation Cellerator is a cell therapy development and manufacturing facility that provides an integrated suite of services spanning cell line development and gene editing, assay development and quality control, process development, GMP manufacturing for Phase I/II clinical trials, fill/finish and cryopreservation, and regulatory support. The facility is purpose-built to translate stem cell-based discoveries from research laboratories into scalable, GMP-compliant cell therapy products suitable for human clinical trials.

Product overview

Novo Nordisk Foundation Cellerator is a unified cell therapy development and manufacturing facility (not a software platform) offering an integrated suite of technical services. The core service encompasses the full cell therapy value chain from starting material development and gene editing through process development, GMP manufacturing, product release, and regulatory support. The service portfolio includes: Cell Line Development & Gene Editing, Assay Development & Quality Control, Process Development, GMP Manufacturing, Fill/Finish & Cryopreservation, Regulatory Support, plus supportive infrastructure with collaborative workspace, centralized procurement resources, and community engagement programs. Operations are scheduled to commence in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Line Development & Gene Editing Access to embryonic stem (ES) and induced pluripotent stem cell (iPSC) lines, support for sourcing and qualification of third-party cell lines, licensing of gene editing and iPSC reprogramming platforms, and initial cell line derivation and banking for cell therapy developers.
• Assay Development & Quality Control Comprehensive assay development including product characterisation, purity/impurity and potency testing, assay validation, and safety testing with virus and microbiology rapid tests for product release.
• Process Development Process development labs facilitating the transition from preclinical proof-of-concept to first human dose, with equipment for adherent and suspension cell culture, cell expansion, differentiation, and scaling for cell therapy programs.
• GMP Manufacturing Specialized GMP manufacturing for Phase I/II clinical trials with focus on quality and compliance, providing scalable and safe production of cell therapy products for therapeutic innovation and patient care.
• Fill, Finish & Cryopreservation Aseptic filling and packaging in GMP compliance with cryopreservation services using state-of-the-art technology to preserve cell viability and function for immediate use or long-term storage.
• Regulatory Support Expert regulatory support for cell therapy approvals including assistance with IND and CTA filings, interactions with regulatory agencies such as the Danish Medicines Agency, and compliance with current guidelines.
• PACE Program (Product Acceleration to Clinical Evaluation) Early engagement program providing collaboration, guidance, resources, and development services to academic researchers and biotech developers working on promising cell therapies, designed to accelerate progress from discovery toward clinical evaluation.

Quantifiable outcome

• First clients expected October 2027 with facility operational and ready for GMP manufacturing

Named customers1 record

Segments4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Ibnova TherapeuticscoreStrategic or Co-development Partner · 10 March 2026First spin-out company from reNEW (Novo Nordisk Foundation Center for Stem Cell Medicine). Cellerator provides CMC, process development, analytics, and GMP-readiness support for Ibnova's vascularised engineered heart tissue therapies for severe heart failure. This represents the first joint regenerative medicine effort enabled across three Novo Nordisk Foundation initiatives (reNEW, BII, and Cellerator).
• reNEW (Novo Nordisk Foundation Center for Stem Cell Medicine)coreStrategic or Co-development PartnerInternational partnership between institutions in Denmark, the Netherlands and Australia for groundbreaking stem cell research and translational science. Provides regenerative biology expertise and scientific continuity for maturation of therapeutic assets. Cellerator supports the translation pathway for treatments developed at reNEW.
• BioInnovation Institute (BII)coreStrategic or Co-development PartnerNovo Nordisk Foundation initiative supporting venture creation and early translation. Through BII's Venture Lab programme, companies like Ibnova receive infrastructure and expertise to translate early science into ventures designed for clinical progress. BII and Cellerator collaborate on integrated translational support.
• Thermo Fisher ScientificcoreStrategic or Co-development PartnerStrategic collaboration to co-host the Cell Therapy Insights Series twice yearly. Thermo Fisher provides scientific and therapeutic development expertise, with Timothy Miller (Global Head, Scientific & Therapeutic Development) moderating panel discussions. The partnership strengthens the bridge from research to patient access.
• Technical University of Denmark (DTU)coreStrategic or Co-development PartnerCellerator located at DTU campus in Lyngby. Collaboration in both construction and operational phases, drawing on DTU's significant expertise in cell manufacturing and related technologies. Engagement with DTU's innovation ecosystem including start-ups. Anders Bjarklev, President of DTU, serves as ecosystem partner.

Scale indicators4 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• RoslinCT: Scotland-based cell therapy CDMO offering GMP manufacturing and process development services for cell and gene therapy developers — closely comparable in scale, GMP focus on clinical-stage material, and academic/biotech target customers.
• Forge Biologics: US-based CDMO focused on gene therapy development, viral vector manufacturing and cell therapy services with a purpose-built GMP facility. Comparable as a single-site, capability-rich CDMO targeting clinical-stage developers in advanced therapies.
• Cell and Gene Therapy Catapult: UK-based cell and gene therapy Catapult operates GMP manufacturing facilities and translational programs for academic and industry developers — directly comparable to Cellerator's mission, public-good model, and Phase I/II manufacturing scope.
• CCRM Nordic: Nordic-focused cell and gene therapy development and manufacturing center established as a partnership with the Centre for Commercialization of Regenerative Medicine. Cellerator's CTO Sarah Callens was previously CTO at CCRM Nordic, where she led process and analytical development, CMC strategy and GMP facility design — making it a close operational and regional peer.
• NecstGen: Netherlands-based cell and gene therapy CDMO providing GMP manufacturing, process development and QC for clinical-stage developers — directly comparable in European regional positioning and Phase I/II manufacturing scope. Cellerator's QA Principal Luis Ricardo previously held a quality role at NecstGen.

Broad incumbents

• Lonza: Global CDMO with a dedicated Cell & Gene Technologies business offering GMP cell therapy process development, manufacturing and fill-finish across multiple sites. Competes with Cellerator in the same service categories but at much greater scale and global reach.
• AGC Biologics: Global biopharmaceutical CDMO with mammalian and cell therapy manufacturing capabilities across multiple geographies. Comparable as a multi-modality CDMO serving clinical-stage biotech and pharma clients including cell therapy programs.
• Catalent: Large global CDMO (now owned by Novo Holdings, the investment arm of the Novo Nordisk Foundation) offering cell therapy development, viral vector manufacturing and clinical supply services. Competes across Cellerator's full capability stack and adds a unique ownership overlap via the NNF group.

Others

• Thermo Fisher Scientific: Cellerator's strategic event partner through the Cell Therapy Insights Series. Thermo Fisher supplies the cell therapy equipment, reagents and consumables stack used inside Cellerator's GMP and process development labs, making it a critical ecosystem enabler rather than a direct CDMO competitor.

Emerging players

• BioCentriq: Cell and gene therapy CDMO based in New Jersey offering process development, GMP manufacturing and analytical services for early-stage developers. Comparable in scale and Phase I/II focus, though with a smaller commercial footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cellerator

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novo Nordisk Foundation Cellerator